Buying This 1 Biotech Stock Now Could Help Make You a Multimillionaire Retiree

By Prosper Junior Bakiny – Mar 8, 2026 at 5:48PM ESTKey PointsVertex Pharmaceuticals' current lineup could drive top-line growth well into the 2030s.The company should launch brand-new products that will take over after that. The stock looks like a great pick to help turn investors into multimillionaires, given enough time.Everyone should save money for retirement, since programs such as Social Security aren't meant to replace workers' entire income and face potential cuts. Building a big nest egg for your post-work life by buying stocks is very possible, but it requires patience, investing in the right companies, and a disciplined buy-and-hold approach. Which stocks should you consider that could help you grow your wealth to several million dollars by the time you retire (assuming a 30-year investment horizon)? Let's consider one biotech company that's worth a second look: Vertex Pharmaceuticals (VRTX 0.86%). Image source: Getty Images. Why Vertex can pull it off Now, assuming an initial investment of $100,000, it would take a compound annual growth rate (CAGR) of 10.5% to grow it to $2 million in 30 years. Maintaining a CAGR of that size over three decades is no easy feat, but buying a stock like Vertex Pharmaceuticals, which has excellent prospects, is a good start. Consider the company's commercial opportunity over the next 13 years or so. Vertex dominates the market for drugs treating a rare disease called cystic fibrosis (CF), which causes thick mucus to build up in the lungs and disrupts breathing. The biotech company's most important products in this niche, Trikafta and Alyftrek, will lose patent exclusivity in 2037 and 2039, respectively. True, CF is a rare disease with only about 112,000 patients in the geographies Vertex targets. However, those patients are now living longer, partly thanks to the company's breakthroughs, and they typically take medicine for their entire lives, so they remain in Vertex's ecosystem. And there are still quite a few patients Vertex can target through new approvals and label expansions. ExpandNASDAQ: VRTXVertex PharmaceuticalsToday's Change(-0.86%) $-3.97Current Price$456.85Key Data PointsMarket Cap$116BDay's Range$450.94 - $459.7252wk Range$362.50 - $519.68Volume59KAvg Vol1.4MGross Margin86.32% Before the sun sets on Vertex's vast CF opportunity, it will launch several new products that should drive growth beyond the next 13 years. Its newest non-CF approvals -- Journavx for acute pain and Casgevy, a gene-editing medicine for beta-thalassemia and sickle cell disease -- should slowly ramp up their sales and contribute somewhat to its financial results. The company has several late-stage candidates targeting diseases with few or no treatment options. Vertex's zimislecel could help restore the ability of Type 1 diabetes patients to make their own insulin, while inaxaplin for APOL-1-mediated kidney disease could be the first approved medicine to target the underlying causes of this disease. Beyond any single product, Vertex Pharmaceuticals has shown itself to be an incredibly innovative company with a management team that's planning far ahead and addressing potential challenges -- like patent cliffs and too much exposure to its CF franchise -- early enough. That makes the stock an excellent candidate to perform well over the long run. The strategy to adopt Although Vertex looks like a great long-term bet, it wouldn't be wise to invest your entire starting capital in this single company. With $100,000 (or whatever amount you have), you should buy many stocks across various industries, including Vertex Pharmaceuticals, and probably add an exchange-traded fund or two to track the performance of major indexes. You should also make sure, if you can, to increase your holdings or buy entirely new stocks fairly regularly, while staying put when equities experience significant downturns. It's that kind of disciplined, patient strategy that can help turn you into a multimillionaire by the time you retire. Investing in a stock like Vertex Pharmaceuticals is just part of the package.Read NextMar 4, 2026 •By Prosper Junior BakinyForget CRISPR Therapeutics: This Gene‑Editing Player Already Boasts the Profits It Dreams OfFeb 26, 2026 •By Prosper Junior BakinyForget Centessa Pharmaceuticals: This Rare‑Disease Specialist Has a Superior Portfolio and PipelineFeb 24, 2026 •By Adria CiminoThe Ultimate Biotech Stock to Buy With $500 Right NowFeb 22, 2026 •By Prosper Junior BakinyCould Vertex Stock Help Turn $100,000 Into $1 Million by 2036?Feb 18, 2026 •By Adria CiminoVertex: The Quiet Biotech Compounder I'd Happily Hold Through Any Market CrashFeb 13, 2026 •By James BrumleyWhy CRISPR Therapeutics Stock Is Up Today (Despite Its Q4 Earnings Miss)About the AuthorProsper Junior Bakiny is a contributing Motley Fool healthcare analyst covering biotechnology, pharmaceuticals, and healthcare stocks.

Before The Motley Fool, Prosper wrote about investing topics ranging from stock market news to private equity for various companies. He holds a master’s degree in corporate finance from the University of Maryland Global Campus.TMFPBakinyStocks MentionedVertex PharmaceuticalsNASDAQ: VRTX$456.85(-0.86%)-$3.97*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.